Results of the phase Ib dose escalation study of MEN1611, a...

Annals of Oncology 2020 / 09 Vol. 31

Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

Piccart, M., Borrego, M. Ruiz, Duhoux, F., Arkenau, H-T., Doger de Spéville, B., Wildiers, H., Campone, M., Tosi, D., Garcia-Corbacho, J., Jimenez, B., Romaní, S. Escrivá-de, Wardley, A.M., Tassone
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.449
Date:
September, 2020
File:
PDF, 83 KB
2020
Conversion to is in progress
Conversion to is failed